Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Exposure of Fluticasone/Formoterol in COPD
NCT00774761Phase 2Completed
- Sponsor
- Dey
- Start
- Nov 2008
- Primary completion
- Apr 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fluticasone propionate nasal spray and formoterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Dey. Primary endpoint: Plasma Area Under the Curve from time 0 to last measurable concentration at 1 week. Started Nov 2008; status: completed.
02
Drugs
fluticasone propionate nasal sprayformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00774761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774761.